Financial PositionThe company has strengthened its cash position through additional financing, extending operations into the third quarter of 2025.
Regulatory SupportD-PLEX100 has received Fast Track and Breakthrough designations, which supports a faster regulatory review process.
Trial ProgressThe SHIELD II trial has successfully enrolled the initial target of 630 subjects, indicating strong trial progress.